US Patent

US8372828 — Therapeutic compositions

Formulation · Assigned to Leo Laboratories Ltd · Expires 2026-12-18 · 1y remaining

Vulnerability score 65/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of stabilizing the anticancer agent ingenol angelate by dissolving it in an aprotic solvent with an acidic buffer.

USPTO Abstract

Ingenol angelate is a potent anticancer agent, and can be stabilized by dissolving it in an aprotic solvent in the presence of an acidic buffer.

Drugs covered by this patent

Patent Metadata

Patent number
US8372828
Jurisdiction
US
Classification
Formulation
Expires
2026-12-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Leo Laboratories Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.